161 results on '"Hojnacki D"'
Search Results
2. Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data
3. sj-doc-2-msj-10.1177_1352458511433304 – Supplemental material for Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis
4. sj-doc-3-msj-10.1177_1352458511433304 – Supplemental material for Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis
5. sj-doc-1-msj-10.1177_1352458511433304 – Supplemental material for Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis
6. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years
7. Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis
8. Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study
9. Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine
10. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5‐year longitudinal study
11. Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis
12. Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow
13. Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis
14. CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study
15. Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls
16. Prospective randomized trial of venous angioplasty in MS (PREMiSe)
17. Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency.
18. Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Patients with Multiple Sclerosis
19. No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis
20. Subtle Lesion Appearance on MRI May Precede Development of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients Treated with Natalizumab (P07.059)
21. Comparison of a 1.5T Standard vs. 3T Optimized Protocols in Multiple Sclerosis Patients (P03.053)
22. Limb Ataxia Originating from Peri-Central Sulcus Demyelinating Lesion in Multiple Sclerosis Patients (P06.176)
23. Successful Treatment of Natalizumab Induced PML with CMX001 and the Side Effects Associated with Its Use (P07.060)
24. Iron Deposition on SWI Filtered Phase in the Subcortical Deep Gray Matter of Clinically Isolated Syndrome Patients May Precede Structure-Specific Atrophy (P03.032)
25. Iron Deposition on SWI-Filtered Phase in the Subcortical Deep Gray Matter of Patients with Clinically Isolated Syndrome May Precede Structure-Specific Atrophy
26. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis
27. Intra- and Extraluminal Structural and Functional Venous Anomalies in Multiple Sclerosis, as Evidenced by 2 Noninvasive Imaging Techniques
28. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS
29. Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study
30. Increased tissue damage and lesion volumes in African Americans with multiple sclerosis
31. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test
32. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis
33. Gender-related differences in MS: a study of conventional and nonconventional MRI measures
34. Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity
35. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
36. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
37. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5‐year longitudinal study.
38. Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis
39. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: A pilot case-control study
40. Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis
41. Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency
42. Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report
43. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis
44. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-β
45. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta.
46. Efficacy and safety outcomes in multiple sclerosis patients treated with mitoxantrone.
47. Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
48. Post-Partum Clinical and Patient-Reported Outcome Changes in Mothers with Multiple Sclerosis: Findings from the NAPPREMS Study.
49. Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis.
50. Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.